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        Plasmacytoid DC (pDC) represent a rare DC 
subset characterized by plasma cell morphology 
and a distinctive surface phenotype (CD4  +  , 
CD45RA  +  , CD123  +  , BDCA-2  +  , BDCA-4  +  , 
CD62L  +  , CLA  +  , and CD11c       ) (  1, 2  ). pDC are 
considered key eff  ector cells in innate antiviral 
immunity because of their peculiar capacity to 
produce massive amounts of type I IFN. Upon 
viral stimulation, pDC diff  erentiate into a unique 
type of mature DC, which directly regulates T 
cell function (  1, 3, 4  ). Circulating pDC directly 
migrate to secondary lymphoid organs through 
the expression of CD62L and some chemotactic 
receptors, namely CXCR4, CXCR3, CCR5, 
and ChemR23 (  5  –  10  ). pDC also infi  ltrate pe-
ripheral tissues in a few pathological conditions, 
such as some skin immune-mediated diseases 
(e.g., systemic lupus erythematosus, lichen pla-
nus, and psoriasis), allergic contact dermatitis 
reactions, and certain tumors (  7, 11  –  14  ). 
  Psoriasis is one of the most common T 
cell  –  mediated infl  ammatory diseases in humans. 
It is characterized by a chronic course with re-
lapses triggered by environmental factors such 
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  Psoriasis is a type I interferon-driven T cell  –  mediated disease characterized by the recruit-
ment of plasmacytoid dendritic cells (pDC) into the skin. The molecules involved in pDC 
accumulation in psoriasis lesions are unknown. Chemerin is the only infl  ammatory chemo-
tactic factor that is directly active on human blood pDC in vitro. The aim of this study was 
to evaluate the role of the chemerin/ChemR23 axis in the recruitment of pDC in psoriasis 
skin. Prepsoriatic skin adjacent to active lesions and early lesions were characterized by a 
strong expression of chemerin in the dermis and by the presence of CD15  +   neutrophils and 
CD123  +  /BDCA-2  +  /ChemR23  +   pDC. Conversely, skin from chronic plaques showed low 
chemerin expression, segregation of neutrophils to epidermal microabscesses, and few pDC 
in the dermis. Chemerin expression was localized mainly in fi  broblasts, mast cells, and 
endothelial cells. Fibroblasts cultured from skin of psoriatic lesions expressed higher levels 
of chemerin messenger RNA and protein than fi  broblasts from uninvolved psoriatic skin or 
healthy donors and promoted pDC migration in vitro in a chemerin-dependent manner. 
Therefore, chemerin expression specifi  cally marks the early phases of evolving skin psoriatic 
lesions and is temporally strictly associated with pDC. These results support a role for the 
chemerin/ChemR23 axis in the early phases of psoriasis development. 
© 2009 Albanesi et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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    RESULTS   
  Chemerin is highly expressed in psoriatic LS skin 
  Based on previous work showing that pDC abundantly infi  l-
trate psoriatic skin, we sought to assess chemerin presence in 
psoriatic plaque lesions. Chemerin expression and distribution 
were investigated by immunohistochemistry in both unin-
volved and LS skin of psoriatic patients and, in parallel, in skin 
of patients aff  ected by atopic dermatitis (AD) or healthy indi-
viduals. Skin biopsies from psoriatic lesions showed numerous 
chemerin  +   cells localized in the dermis and scattered through-
out the T cell  –  rich infi  ltrate (  Fig. 1 A  ).   In contrast, only a few 
chemerin immunoreactive cells were detected in the dermis of 
uninvolved psoriatic skin or healthy skin (  Fig. 1, B and C  , re-
spectively) or in the dermis of AD lesions (  Fig. 1 D  ). Double 
staining analysis revealed that the majority of chemerin  +   cells 
were dermal cells with a fi  broblast morphology coexpressing 
vimentin, which is a typical mesenchymal cell marker (  Fig. 2, 
A and B  ).   Some of the dermal chemerin  +   cells also coexpressed 
FVIII  +  , which stains blood endothelial cells (    20% of dermal 
vessels), and     5% of total chemerin  +   cells expressed c-kit  +  , 
which is a mast cell marker (  Fig. 2, C and D  , respectively). 
Conversely, chemerin immunoreactivity did not colocalize 
with CD15  +  , CD3  +  , BDCA-2  +  , CD1a  +  , CD1b  +  , or CD14  +   
markers (  Fig. 2, E and F  ; and not depicted). Finally, expression 
of chemerin immunoreactivity was also observed in the epi-
dermal compartment of healthy or uninvolved psoriatic skin 
(  Fig. 1, B and C  ). On the contrary, and in agreement with 
a previous study (  26  ), LS psoriatic plaques displayed a weak 
as trauma, infections, stress, and drugs (  15, 16  ). Recently, it 
was reported that resting pDC infi  ltrate lesional (LS) skin of 
patients aff  ected by psoriasis and, once activated, produce 
high levels of IFN-     that in turn drive the local activation 
and expansion of pathogenetic T cells (  17, 18  ). These are 
mainly represented by Th17 and Tc1 lymphocytes and are 
directly responsible for the development of psoriatic skin le-
sions (  19, 20  ). The chemotactic factors involved in the re-
cruitment of pDC to prepsoriatic skin are currently unknown. 
Accumulating evidence supports a role for chemerin and its 
cognate receptor ChemR23 in the recruitment of pDC into 
pathological peripheral tissues (  7, 13, 21  ). Chemerin is a pro-
tein, originally isolated from infl  amed biological fl  uids (i.e., 
ovarian cancer ascites and rheumatoid arthritis synovial fl  u-
ids), which is synthesized as an inactive precursor protein that 
binds ChemR23 with low affi   nity (  21, 22  ). Prochemerin can 
be rapidly converted into a full ChemR23 agonist by the 
proteolytic removal of the last six or seven amino acids by 
neutrophil-derived proteases (elastase and cathepsin G), mast 
cell products (tryptase), proteases of the coagulation cascade 
(  23, 24  ), and certain bacterial proteases (  25  ). 
  The aim of the present study was to evaluate the possible 
role of the chemerin/ChemR23 axis in the recruitment of pDC 
to the skin of psoriasis patients. This study shows that chemerin 
expression selectively marks the early phases of psoriasis le-
sions and strongly parallels pDC and neutrophil dermal infi  l-
tration. Collectively, these results propose chemerin as a key 
protein in the early phases of psoriasis lesion development. 
    Figure 1.         Chemerin expression in healthy and diseased skin  . Immunohistochemistry was performed with an anti-chemerin mAb (red) on the 
following: a, LS (12 different subjects); b, nonlesional (NLS; 10 different subjects); c, normal skin from healthy donors (6 different subjects); and d, AD LS skin 
(5 different subjects). Bars, 20   μ  m. Chemerin was highly expressed in the dermis of psoriatic lesions but not in NLS psoriatic or healthy skin. Few 
chemerin  +   cells were present in the dermis of AD LS skin. In addition, chemerin immunoreactivity was intense throughout the epidermis of healthy and 
NLS psoriatic skin, whereas in LS it was weak and confi  ned to the suprabasal layer keratinocytes. The fi  gure is representative of the results on skin biop-
sies obtained from all the different donors indicated.     JEM VOL. 206, January 19, 2009 
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P   <   0.01), which is in agreement with mRNA data. Among 
the diff  erent experimental conditions tested, only calcitriol in-
duced a signifi  cant up-regulation of chemerin production 
(P   <   0.01). Retinoic acid induced only a minor increment of 
chemerin release (  Fig. 3 B  ), whereas all the other agonists 
tested did not show any eff  ect on chemerin basal production 
independent of the source of fi  broblasts (not depicted). The 
three fi  broblast types investigated, namely from healthy donor 
skin, and NLS and LS skin from the same patients with psoriasis 
showed the same degree of chemerin regulation independent 
of basal levels of chemerin production (  Fig. 3 B  ). 
  In vitro migration of pDC in response to supernatants 
from psoriatic fi  broblast cultures 
  The ability of fi  broblast-derived chemerin to induce pDC mi-
gration was evaluated in vitro in transmigration experiments. 
chemerin expression in the epidermis that was confi  ned to the 
keratinocyte suprabasal layer (  Fig. 1 A  ). 
  Chemerin production by fi  broblasts was further evaluated 
in vitro using primary cell cultures. Consistent with the 
immunohistochemical fi  ndings, chemerin messenger RNA 
(mRNA) levels, evaluated by quantitative PCR, were signif-
icantly higher (  >  50%; P   <   0.01) in fi  broblasts obtained from 
LS psoriatic skin compared with those from NLS skin of the 
same patients (  Fig. 3 A  ).   Fibroblasts from healthy donors ex-
pressed levels of chemerin mRNA that were only slightly re-
duced compared with fi  broblasts from uninvolved skin of 
psoriatic patients, suggesting that the diff  erent genetic back-
ground of psoriatic cells does not have an infl  uence on the basal 
levels of chemerin expression. Regulation of chemerin pro-
duction was investigated at the protein level in cultures of fi  bro-
blasts stimulated with some of the proinfl  ammatory cyto  kines 
that characterize psoriatic plaque lesions (e.g., IFN-    , IFN-    , 
TNF-    , and CXCL8) (  27, 28  ) or with factors known to regulate 
fi  broblast growth, such as retinoic acid, calcitriol, and TGF-    . 
Basal chemerin release from healthy donor and NLS psoriatic 
skin fi  broblasts was similar (321   ±   31 vs. 436   ±   84 pg/ml; 
mean   ±   SD; P = 0.07), whereas LS psoriatic fi  broblast cul-
tures released higher amounts of chemerin (702   ±   110 pg/ml; 
    Figure 2.         Chemerin expression colocalizes with vimentin  +  , FVIII  +  , 
and c-kit  +   cells  . Chemerin expression was evaluated by double immuno-
histochemistry in psoriatic plaque lesions. Anti-chemerin mAb (red) immuno-
reactivity was detected in dermal cells having fi  broblast-like morphology (a). 
Double-staining analysis revealed that chemerin colocalizes with vimentin 
(b), FVIII (c), and c-kit (d) but not with CD15 (e) or CD3 (f) staining (all blue). 
The fi  gure shows the staining of one biopsy that is representative of eight 
different patients evaluated. Arrows indicate cells that are double positive 
for chemerin and for vimentin (b), FVIII (c), or c-kit (d). Bars, 20   μ  m.     
    Figure 3.         Selective expression of chemerin by fi  broblasts isolated 
of psoriatic LS skin  . (A) Chemerin expression was determined in fi  bro-
blast primary cultures prepared from skin cells isolated from healthy do-
nors (fi  ve donors) as well as NLS and LS skin of the same psoriatic patients 
(six donors). Levels of mRNA expression were determined after normaliza-
tion with 18S ribosomal RNA values. Horizontal lines indicate mean values 
for each experimental group. (B) Chemerin protein expression was evalu-
ated by ELISA on supernatants from fi  broblast cultures derived from NLS 
and LS psoriatic patients (10 donors) and healthy subject (10 donors) skin 
cells. Cells were stimulated or not with 10   μ  M retinoic acid (ATRA) or 1   μ  M 
calcitriol (Calc) for 24 h. Data are represented as fold of induction, with 
basal chemerin release being 321   ±   31, 436   ±   84, and 702   ±   110 pg/ml for 
healthy, NLS, and LS psoriatic cells, respectively. Error bars are SD of mean 
values of 10 different donors per group. *, P   <   0.05.     252 RECRUITMENT OF PLASMACYTOID DC IN PSORIASIS   | Albanesi et al. 
induced pDC migration (unpublished data). pDC migration 
was not aff  ected by the presence of blocking mAbs to CXCR4 
or CXCR3, two potentially relevant chemotactic receptors for 
pDC (  Fig. 4 B  ). Furthermore, migration to LS skin fi  broblast 
conditioned medium was inhibited by pretreatment of cells 
with recombinant chemerin (  Fig. 5 A  ).   Finally, conditioned 
medium obtained from LS skin fi  broblast cultures, but not 
from healthy donors, induced the phosphorylation of ERK1/2 
in H460 epithelial cell line stably transfected with ChemR23 
(  Fig. 5 B  ). Altogether, these data strongly suggest that fi  bro-
blasts from LS skin constitutively release biological active 
chemerin that promotes pDC migration. 
  pDC infi  ltration correlates with chemerin expression 
and marks early psoriatic lesions 
  Only a subset of psoriatic LS skin samples showed a chemer-
in  high   phenotype (  Fig. 6 A  , a), whereas other skin samples 
could be defi  ned as chemerin  low   based on the modest number 
of chemerin  +   cells (6.3-fold lower;   Fig. 6, A   [a vs. b]   and C  ).   
Chemerin  high  , but not chemerin  low  , psoriatic lesions exhibited 
a prominent infi  ltrate of ChemR23  +   cells (  Fig. 6, A   [d and e, 
  Fig. 4 A   shows that blood-purifi  ed pDC were induced to 
transmigrate across an endothelial cell monolayer by condi-
tioned medium obtained from LS skin fi  broblast cultures but 
not from NLS skin or healthy donor-derived fi  broblast 
supernatants.   This migration was dependent on chemerin be-
cause it was completely blocked in the presence of an anti-
ChemR23  –  blocking mAb (  Fig. 4, A and B  ). The specifi  city of 
the antibody was confi  rmed by the lack of eff  ect on CXCL12-
    Figure 4.         Psoriatic fi  broblasts induced pDC migration in vitro  . Su-
pernatants from cultured fi  broblasts were tested for their ability to induce 
blood-purifi  ed pDC migration in Transwell experiments. (A) pDC transmi-
gration was assessed using supernatants collected from healthy (HS; 1:9 
dilution), NLS (1:9 dilution), and LS (1:81 dilution) psoriasis fi  broblast 
cultures or 100 pM of recombinant chemerin. Anti-ChemR23 antibody 
was used at 10   μ  g/ml. (B) Migration of pDC to LS psoriasis supernatants 
was completely inhibited in the presence of a blocking anti-ChemR23 
mAb (IgG2b) but not by an isotype-matched mAb (Ist-Ctrl; anti-CCR6 
mAb) or blocking anti CXCR4 and CXCR3 mAbs. Squares represents the 
results obtained from normal subjects (white), psoriasis patients (gray), 
and psoriasis patients treated with control mAbs (black). *, P   <   0.01 versus 
respective control group (i.e., without blocking mAb). Results are ex-
pressed as single values obtained using supernatants generated from 
individual cultures obtained from 10 and 7 different donors investigated 
(A and B, respectively). Horizontal lines indicate mean values for each 
experimental  group.   
    Figure 5.         LS skin fi  broblasts from psoriatic lesions release bioac-
tive chemerin.   (A)  Blood-purifi  ed pDC were preincubated with 300 pM of 
recombinant human chemerin at 37  °  C. Cells were then washed and tested 
in Transwell assay for their ability to transmigrate an endothelial cell 
monolayer in response to medium (Ctrl), 100 pM chemerin, or LS superna-
tant (1:81 dilution). Data were obtained with supernatants obtained from 
fi  ve different donors. *, P   <   0.05. Horizontal lines indicate mean values for 
each experimental group. (B) H460 cells transfected with the empty vec-
tor (mock) or ChemR23 were stimulated with fi  broblast-derived superna-
tant from LS skin (1:81 dilution) or healthy donors (HS; 1:9 dilution). 
Anti-ChemR23 mAb was used at 10   μ  g/ml. Western blots were performed 
as detailed in Materials and methods.     JEM VOL. 206, January 19, 2009 
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respectively]   and C  ) and CD123  +  /BDCA-2  +   pDC in the 
dermis (  Fig. 6 A  , g and h; and Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20080129/DC1). Dou-
ble staining showed that ChemR23  +   cells were mostly 
CD123  +   or BDCA-2  +   (    60 and 85%, respectively) with 
some CD11c  +   cells (    15%). Conversely, ChemR23 was not 
coexpressed by c-kit  +  , CD3  +  , CD15  +  , or CD14  +   cells (Fig. S1 
and not depicted). In chemerin  low   biopsies, the anti-CD123 
mAb only stained blood vessels (  Fig. 6 A  , panel h). The lack 
of chemerin expression in uninvolved psoriatic skin corre-
lated with the absence of ChemR23  +   cells in the dermis 
(  Fig. 6 A  , a and d, insets). 
  Previous work described infi  ltration of dermis and epi-
dermis by neutrophils as discriminating the early phase of 
psoriasis development from the chronic phase, which is char-
acterized by the accumulation of neutrophils in the epidermis 
to form focal subcorneal aggregates (  29  ). Other immunologi-
cal aspects of chronic lesions include a prominent CD8  +   T 
cell infi  ltrate in the epidermis and a strong ICAM-1 positivity 
of basal layer keratinocytes (  30  ). To better understand the 
regulation of chemerin in psoriatic skin, the expression of 
chemerin was correlated with the degree and distribution 
of CD15  +   neutrophils as well as CD8  +   and ICAM-1  +   cells. 
  Fig. 6 B   (j and k) shows that the presence of CD15  +   cells in the 
mid and papillary dermis and in the epidermis was exclusively 
associated with the chemerin  high   phenotype and with the pres-
ence of a prominent infi  ltrate of CD123  +   pDC (  Fig. 6 A  , g) 
as well as c-kit  +   mast cells (Fig. S2 a, available at http://
www.jem.org/cgi/content/full/jem.20080129/DC1). Con-
versely, in chemerin  low   biopsies, CD15  +   cells were localized 
only in epidermal microabscesses (  Fig. 6 B  , k). Chemerin  low   
skin lesions also showed the markers of chronic infl  amma-
tion, such as CD8  +   T cell infi  ltration in the epidermis and the 
intense ICAM-1 immunoreactivity of basal keratinocytes 
(  Fig. 6 B  , n and q). CD11c  +   cells were present in a similar 
manner in both chemerin  high   and chemerin  low   biopsies (Fig. S3, 
a and b, available at http://www.jem.org/cgi/content/full/
jem.20080129/DC1). Similarly, CXCL10 and CXCL12 
expression was equally present in early (chemerin  high  ) and 
chronic (chemerin  low  ) LS skin (Fig. S3, d, e, g, and h). AD 
skin lesions presented only a negligible infi  ltration of pDC 
(  Fig. 6 A  , i), as previously described (  14  ), which was not as-
sociated with dermal chemerin  +   cells (  Fig. 6 A  , c) or CD15  +   
neutrophils (  Fig. 6 B  , l). The presence of CD8  +   T lympho-
cytes (  Fig. 6 B  , o), CD11c  +   DC (Fig. S3, c), and focal ICAM-1 
positivity (  Fig. 6 B  , r) in the epidermis of AD skin is consis-
tent with previous reports ( 31  ). The quantifi  cation of chemerin  +  , 
ChemR23  +  , CD123  +  , BDCA-2  +  , CD15  +  , CD8  +  , c-kit  +  , and 
CD11c  +   cells in the diff  erent experimental conditions is re-
ported in   Fig. 6 C  .      Figure 6.         Infi  ltration of pDC in psoriatic LS skin correlates with 
the expression of chemerin and the presence of neutrophils in the 
dermis  . (A and B) Immunohistochemistry was performed using sections 
from AD lesions (  n   = 5) and from psoriatic skin showing a chemerin  high  
(  n   = 8) and chemerin  low   ( n   = 12) phenotype. Bars, 20   μ  m. The insets 
represent stainings of uninvolved psoriatic skin. Arrows point to posi-
tive cells. (C) Positive cells were enumerated in the dermis of psoriatic 
uninvolved skin (NLS) in chemerin  high ,  chemerin low  , and AD skin sections 
(  n   = 3). Slides were analyzed blind by two observers and positive cells 
were counted in 10 adjacent fi  elds at a magnifi  cation of 200  ×  . Results 
are expressed as the mean number of positive cells   ±  SD. *, P   <   0.05 
versus NLS skin.     
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    DISCUSSION   
  Chemerin is the only infl  ammatory chemotactic factor known 
to induce pDC migration in vitro (  10  ). In vivo, chemerin 
expression was shown to correlate with pDC infi  ltration into 
peripheral tissues during autoimmune diseases such as sys-
temic lupus erythematosus and lichen planus (  7, 13  ). In this 
paper, we report that expression of chemerin is temporally 
strictly associated with pDC recruitment in psoriatic skin bi-
opsies. Psoriasis is an immune-mediated disease characterized 
by a profound T cell dysregulation (  15, 16  ). Growing evidences 
propose a pivotal role for pDC in the triggering of the in-
fl  ammatory reactions associated with psoriasis, and the current 
model depicts pDC as key eff  ector cells that drive the activa-
tion of pathogenetic T cells through their ability to release 
high levels of IFN-     (  17, 18  ). Previous studies have focused 
on the role of innate immunity in psoriasis. Neutrophils and 
mast cells are known to infi  ltrate psoriasis skin plaque lesions 
during the early phases of the disease, whereas both cell types 
are more rarely found in the late chronic phase ( 32  ). Immuno-
histological features of chronic lesions are also character-
ized by a prominent CD8  +   T cell infi  ltrate in the epidermis 
  Finally, to defi  nitively establish whether chemerin expres-
sion might be an early event leading to the initial infi  ltration 
of pDC in psoriatic skin, chemerin expression and pDC infi  l-
tration were investigated in NLS prepsoriatic skin adjacent to 
newly developed plaque lesions.   Fig. 7   (b and h) shows that 
chemerin was expressed in the dermis of prepsoriatic skin and 
was associated with the initial, still limited infi  ltration of 
BDCA-2  +   (  Fig. 7  ) and CD123  +   (not depicted) pDC.   Dermal 
chemerin expression was further increased in the proximal 
plaque lesions and was associated with extensive infi  ltration of 
BDCA-2  +  /CD123  +   pDC (  Fig. 7  , c and i; and not depicted). 
Both chemerin expression and pDC recruitment was not ob-
served in the dermis of distant NLS psoriatic skin (  Fig. 7  , 
a and g). In contrast, CXCL10 expression was detectable only 
within the plaque lesions and was confi  ned to basal layer epi-
dermis in both adjacent and 3-cm distant NLS psoriatic skin 
(  Fig. 7, d-f  ), showing a pattern of expression diff  erent from 
that of chemerin and pDC infi  ltration. Collectively, these re-
sults indicate that chemerin expression is an early event in 
psoriasis plaque development, and it precedes and parallels the 
recruitment of pDC into developing skin lesions. 
    Figure 7.         Chemerin is highly expressed in prepsoriatic skin where BDCA-2  +   pDC start to be accumulated.   Immunohistochemistry was per-
formed using sections from early psoriatic plaques at sites of peripheral lesions (LS) together with the adjacent prepsoriatic NLS skin and biopsies from 
normal skin appearing 3 cm distant from the evolving plaques of the same patients (fi  ve total patients examined). Arrows indicate cells that are positive 
for chemerin (b and c) or BDCA-2 (h and i). Bars, 20   μ  m.     JEM VOL. 206, January 19, 2009 
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presence of an anti-ChemR23 blocking antibody with no 
eff  ect of anti-CXCR3 and -CXCR4 antibodies. Furthermore, 
pDC migration to psoriatic skin fi  broblast supernatants was 
completely inhibited (desensitized) by a precedent exposure of 
the cells to recombinant chemerin. Altogether, these results 
strongly indicate that chemerin is the main, if not the only, 
protein responsible for the pDC chemotactic activity that is 
present in the conditioned medium of psoriatic skin fi  broblasts. 
Taking into consideration that fi  broblasts from healthy and 
NLS psoriatic skin also release chemerin/prochemerin, the se-
lective ability of psoriatic fi  broblasts to promote pDC migra-
tion is likely to be crucially regulated by the concomitant 
higher expression of proteases by these cells and, thus, by their 
higher effi   ciency in generating bioactive chemerin (  36  ). 
  To better understand the nature of the signals present 
within the psoriatic infl  ammatory milieu that is responsible for 
the induction of chemerin production, fi  broblasts at early cul-
ture passages were stimulated with proinfl  ammatory cytokines 
and growth factors that characterize psoriatic lesions such as 
IFN-    , IFN-    , TNF-    , CXCL8, retinoic acid, calcitriol, and 
TGF-    . Among the diff  erent experimental conditions inves-
tigated, only calcitriol and, to a lesser extent, retinoic acid 
were able to induce the up-regulation of chemerin protein re-
lease. Therefore, as previously described for endothelial cells 
(  7  ), the mechanisms that govern chemerin expression in path-
ological conditions still need to be fully elucidated. 
  Immunohistochemistry analyses also showed a diff  use 
chemerin expression in the epidermis. Chemerin epidermal 
expression was higher in healthy and uninvolved psoriatic 
skin than in plaque lesions. The biological role of chemerin 
in the epidermis is unknown, but it can be speculated that 
under homeostatic conditions chemerin may represent a ready-
to-use mechanism to rapidly recruit eff  ector cells upon the 
generation of danger signals. Recently, chemerin was shown 
to play a role in the resolution of the infl  ammatory process at 
the mucosal sites by promoting the clearance of epithelial bound 
neutrophils through a CD55/ICAM-1  –  dependent mecha-
nism (  37  ). This function might sustain the transmigration of 
neutrophils in the parakeratotic areas as observed in chronic 
psoriatic skin, and it is consistent with the expression of chemerin 
found both in vitro and in vivo in diff  erentiated keratinocytes 
(  Fig. 1 A   and not depicted). The possible antiinfl  ammatory 
action of chemerin in the epidermis was also suggested in a 
previous study showing the up-regulation of chemerin 
(Tig-2) in psoriatic epidermis after topical application of taz-
arotene, an antipsoriatic synthetic retinoid (  26  ). In contrast, 
calcitriol, an eff  ective antipsoriatic agent (  38  ), was the most 
potent inducer of chemerin in cultured fi  broblasts. Finally, a 
recent study reported that chemerin exhibits antiinfl  amma-
tory activity on macrophages in vitro and in vivo in a prote-
olysis-dependent fashion (  39  ). Therefore, chemerin might 
have a dual opposite role during the evolution of psoriatic 
skin lesions: fi  rst, a crucial role in the recruitment of patho-
genetic pDC during the early phases of the disease when ex-
pressed in the dermis; and subsequently, during the chronic 
phase, the expression of chemerin in the epidermis may favor 
and by ICAM-1 expression by basal layer keratinocytes (  30  ). 
In addition, CD11c  +   iNOS  +   myeloid DC also infi  ltrate pso-
riatic lesions (  32, 33  ). These data indicate that psoriatic lesions 
markedly change their infl  ammatory cell profi  le according to 
the development stage, with diff  erent cell types playing dis-
tinct roles in earlier versus later stages. 
  In this paper, we report that in psoriatic skin lesions, pDC 
accumulation is almost exclusively associated with the con-
comitant presence of neutrophils and mast cells in the dermis. 
In contrast, psoriatic skin specimens characterized by the pres-
ence of intraepidermal neutrophils and CD8  +   T cells, ICAM  +   
keratinocytes, and a few c-kit  +   dermal mast cells were associ-
ated to a scanty presence of pDC. The majority of CD123  +   
and BDCA-2  +   pDC expressed ChemR23, the chemerin re-
ceptor, and chemerin expression in the dermis was only 
observed in association with pDC infi  ltration. Analysis of un-
involved prepsoriatic skin that was adjacent to active plaque 
lesions demonstrated that chemerin is already expressed in 
the dermis in pre-LS sites, where pDC start to become re-
cruited. Therefore, chemerin expression represents an early 
event that precedes and strictly parallels accumulation of pDC 
and clinical expression of psoriasis. Moreover, recruitment of 
pDC in psoriatic skin lesions is associated with infi  ltration of 
neutrophils and numerous mast cells in the dermis. In this 
context, it is interesting to note that activated neutrophils 
and mast cells can convert prochemerin into active chemerin 
through the release of cathepsin G, elastase, and tryptase (  23, 24  ). 
These proteolytic enzymes can also regulate keratinocyte 
proliferation, although their precise role in psoriasis patho-
genesis is still elusive (  34, 35  ). Of note, immunohistochemi-
cal stainings of CXCL12 and CXCL10 showed that these two 
chemokines were equally expressed in chronic versus early 
psoriatic skin lesions (Fig. S3), arguing against a direct role in 
pDC recruitment into psoriatic lesions. To confi  rm the spec-
ifi  city of these fi  ndings, we studied LS AD skin, which did 
not express chemerin and was scantly infi  ltrated by pDC. 
  In psoriatic dermis, chemerin immunoreactivity was ob-
served in endothelial cells, mast cells, and fi  broblasts. Chemerin  +   
blood vessel endothelial cells have been also observed in the 
skin of lupus erythematosus and lichen planus patients. In ad-
dition, chemerin is expressed by high endothelial cells in the 
lymph node (  7, 13  ). The expression of chemerin by mast cells 
represents a new fi  nding, and it is interesting in light of the 
ability of these cells to generate active chemerin through the 
release of tryptase. However, fi  broblasts apparently represent 
the major source of chemerin in psoriatic dermis. This in vivo 
fi  nding was further substantiated in vitro by the use of primary 
cell cultures. Fibroblasts isolated from LS skin expressed higher 
levels of chemerin mRNA than cells obtained from unin-
volved skin of the same patients or skin obtained from healthy 
donors. Moreover, only supernatants of fi  broblasts obtained 
from LS skin of psoriatic patients, and not from healthy donor 
or NLS psoriatic skin, induced the migration of pDC in vitro 
and activated ERK1/2 phosphorylation, which is an early step 
of chemotactic receptor signaling cascade, in ChemR23-trans-
fected cells. These activities were completely blocked in the 256 RECRUITMENT OF PLASMACYTOID DC IN PSORIASIS   | Albanesi et al. 
were investigated, according to the manufacturer  ’  s instructions, using an 
ELISA kit (R  &  D Systems) which does not discriminate between pro-
chemerin and chemerin. 
  RNA isolation and real-time RT-PCR.     Total RNA was extracted from 
fi  broblasts using TRIzol reagent (Invitrogen), treated with DNase (Pro-
mega), and purifi  ed using an RNA isolation kit (QIAGEN). mRNA was re-
verse transcribed into complementary DNA using the Moloney murine 
leukemia virus RT and random hexamers (Applied Biosystems). RT-PCR 
products were analyzed by quantitative real-time RT-PCR in the following 
TaqMan Gene Expression Assays of target genes: chemerin, HS001611209_g1; 
and 18S, HS99999901 as an endogenous control (Applied Biosystems). 
Fluorescence intensity was analyzed by the ABI PRISM SDS 7000 PCR In-
strument (Applied Biosystems). The levels of chemerin expression were de-
termined by normalizing to 18S ribosomal RNA expression. The fold 
induction value for triplicate wells was averaged, and data were presented as 
the mean   ±   SD of fi  ve (HS) and six (NLS and LS) fi  broblast cultures ob-
tained from diff  erent donors. 
  Transendothelial migration assay.     Transendothelial migration assay was 
evaluated using 24-well Costar Transwell chambers (5-  μ  m pore size; Corn-
ing). HUVEC (passage   <  5) were subcultured to confl  uent monolayers on 
Transwell inserts precoated with gelatin. Monolayers were rinsed with che-
motaxis medium (RPMI containing 10% FCS) before use. 100   μ  l DC sus-
pension (10  6   cells/ml) was seeded in the upper chamber and 600   μ  l of 
chemoattractant or fi  broblast conditioned medium were added to the lower 
well. The chamber was incubated at 37  °  C in humidifi  ed atmosphere in the 
presence of 5% CO  2   for 4 h. Migrated cells were recovered from the lower 
well, counted, and the results were expressed as the percentage of input cells. 
In some experiments, a ChemR23 (clone 4C7, IgG2b), CCR6 (IgG2b; 
R  &  D Systems), CXCR4 (R  &  D Systems), and CXCR3 blocking mAbs 
were used during the assay (  7  ). For desensitization experiments, pDC were 
preincubated with 100 pM of recombinant chemerin at 37  °  C for 30 min, 
washed, and subsequently tested in chemotaxis experiments. Each experi-
ment was performed in duplicate and results represent mean values of single 
experiments performed using conditioned media generated using fi  broblasts 
from 10 diff  erent donors for each experimental group. 
  Cell stimulation and Western blotting.     H460 epithelial cells were trans-
fected by electroporation with pcDNA3.1 containing the full length 
ChemR23 ORF (provided by M. Ruiz Rosquete, University of Brescia, 
Brescia, Italy). Transfected cells were selected in the presence of neomycin 
and cloned. Membrane expression of ChemR23 was evaluated by FACS 
analysis. H460 cells transfected with the empty vector (mock) were used as 
negative control. Cells were incubated with supernatants obtained from 
healthy skin (HS; 1:9 dilution) or LS psoriasis skin (1:81 dilution) for 5 min. 
Phosphorylated ERK1/2 and total ERK2 were detected after western blot-
ting using specifi  c mAbs (clone #9101 [Cell Signaling Technology] and 
clone D-2 [Santa Cruz Biotechnology]) and ECL (GE Healthcare). 
  Statistical analysis.     Wilcoxon  ’  s signed rank test was used (SigmaStat; Jan-
del) to compare diff  erences in mRNA chemerin content in healthy and dis-
eased fi  broblasts. P-values   ≤  0.05 were considered signifi  cant. 
  Online supplemental material.     Fig. S1 shows that in the dermis of pso-
riatic skin, ChemR23 expression colocalizes with myeloid DC (CD11c  +  ) 
and pDC (CD123  +   and BDCA2  +  ) markers. Fig. S2 shows that c-kit  +   
mast cells highly infi  ltrate the dermis of chemerin  high   psoriatic plaques but 
not chemerin  low   and AD skin lesions. Fig. S3 shows that CXCL10 and 
CXCL12 are expressed in both chemerin  high   and chemerin  low   biopsies and 
that the expression of these two chemokines does not correlate with pDC 
infi  ltration. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20080129/DC1. 
  We thank Michel Ruiz Rosquete for providing H460-ChemR23 cells and Fabio 
Facchetti and William Vermi for helpful discussion. 
leukocyte clearance from infl  amed tissue and restoration of 
skin homeostasis. 
  In conclusion, we identifi   ed the chemerin/ChemR23 
axis as a new important player in the pathogenesis of psoriasis. 
The concomitant presence of chemerin, pDC, neutrophils, 
and mast cells during the early phases of the disease proposes 
chemerin as a target for prevention and early therapeutic in-
tervention in psoriasis. 
  MATERIALS AND METHODS 
  Tissue samples.     For immunohistochemistry, 4-mm punch biopsies were 
taken from LS (involved) skin of adult patients with early lesions (  <  10 d; 
  n   = 8) and late plaque psoriasis (  >  2 mo;   n   = 12). Biopsies were also obtained 
from patients with chronic AD (  n   = 5) and normal skin of healthy subjects 
undergoing plastic surgery (  n =   10). For six psoriatic patients, a skin biopsy 
from NLS normal-appearing (uninvolved) skin distant from the plaques was 
also taken. Biopsies were also taken from early plaques at sites of peripheral 
lesions together with the adjacent normal-appearing skin (NLS prepsoriatic 
skin) and from normal-appearing skin 3 cm distant from the evolving plaques 
of the same patients (  n   = 5). Biopsies were taken after informed consent and 
the study was approved by the Ethical Committee of the Istituto Dermo-
patico dell  ’  Immacolata (IDI)  –  IRCCS (Rome, Italy). Patients did not receive 
topical or systemic therapy for at least 2 wk before the study. Fibroblast cul-
tures were established from 6-mm punch biopsies obtained from both in-
volved and uninvolved skin of psoriatic patients (  n   = 10), from uninvolved 
skin of AD patients (  n   = 5), and from healthy subjects (  n   = 6). 
  Immunohistochemistry.     Skin samples were fi  xed in 10% formalin and em-
bedded in paraffi   n. 5-  μ  m sections were dewaxed and rehydrated. After quench-
ing endogenous peroxidase, achieving antigen retrieval, and blocking nonspecifi  c 
binding sites, sections were incubated with mAbs against Chemerin (IgG1 clone 
14G10; 1:40 dilution), ChemR23 (IgG2b clone 4C7; 1:20 dilution), CD117/
c-kit (Leica; 1:50 dilution), CXCL10 (Santa Cruz Biotechnology, Inc.; 1:100 
dilution), CXCL12 (R  &  D Systems; 1:50 dilution), and BDCA-2 (Miltenyi 
Biotec). mAbs against CD15 (1:100), CD3 (1:20 dilution), CD11c (1:20), and 
CD123 (1:50) were obtained from BD, whereas anti-vimentin (1:100) and anti-
FVIII/vWF (1:10) were purchased from Dako. Secondary biotinylated mAbs 
and staining kits were obtained from Vector Laboratories. Single stainings were 
developed using 3-amino-9-ethylcarbazole (Vector Laboratories). Double 
immunostaining was developed using the avidin-biotin peroxidase or avidin-
biotin-alkaline phosphatase system and the chromogens 3-amino-9-ethyl-
carbazole and Blue Vector (Vector Laboratories). Occasionally, sequential 
immunohistochemistry was performed. As a negative control, primary Abs were 
omitted or replaced with an irrelevant isotype-matched mAb. Figures depict one 
experiment that is representative of all the patients investigated. The complete 
tissue bank collected for this study (Tissue samples) was probed with the full set 
of antibodies described in the Results section, and the number of subjects inves-
tigated in each experiment is detailed in the fi  gure legends. 
  Fibroblast cultures.     Dermal samples obtained from skin biopsies were 
placed in a dry cell culture plate for 10 min to allow adherence to the poly-
styrene surface of the culture plate. DME (Biochrom KG) supplemented 
with 10% FCS, 4 mM glutamine, 100 U/ml penicillin, and 100 mg/ml 
streptomycin (all from Biochrom KG) was added. Fibroblast outgrowth was 
monitored by light microscopy. At 70  –  80% confl  uence, cells were detached 
with 0.05% trypsin/0.02% EDTA (Biochrom KG) and then frozen or sub-
cultured in the same medium. Second- or third-passage fi  broblasts were used 
in all experiments, with cells cultured in 6-well plates. The following indi-
vidual cell cultures obtained from diff  erent patients were tested: LSl skin 
psoriasis (  n   = 12); NLS skin psoriasis (  n   = 10); healthy skin (HS;   n   = 6); and 
AD (  n   = 5). Treatments of fi  broblast cultures with 200 U/ml of recombinant 
human IFN-    , 500 U/ml IFN-    , 50 ng/ml TNF-    , 10 ng/ml TGF-    , 
10 mM CXCL8 (all from R  &  D Systems), 10   μ  M retinoic acid, or 1   μ  M cal-
citriol (both Sigma-Aldrich) were also performed. Chemerin protein levels JEM VOL. 206, January 19, 2009 
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